Low expression of the myeloid differentiation antigens CD65s, a feature of poorly differentiated AML in older adults: Study of 711 patients enrolled in ECOG trials

Leukemia

Volumn 17, Issue 8, 2003, Pages 1544-1550

  Paietta, E ^a   Neuberg, D ^b   Bennett, J M ^c   Dewald, G ^d   Rowe, J M ^e   Cassileth, P A ^f   Cripe, L ^g   Tallman, M S ^h   Wiernik, P H ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF ROCHESTER   (United States)

^d MAYO CLINIC   (United States)

^e TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^f UNIVERSITY OF MIAMI   (United States)

^g INDIANA UNIVERSITY   (United States)

^h NORTHWESTERN UNIVERSITY   (United States)

Author keywords

AML in the elderly; CD65s; Immunophenotype

Indexed keywords

4 HYDROPEROXYCYCLOPHOSPHAMIDE; AMSACRINE; ANTHRACYCLINE; CD11B ANTIGEN; CD14 ANTIGEN; CD15 ANTIGEN; CD19 ANTIGEN; CD2 ANTIGEN; CD24 ANTIGEN; CD33 ANTIGEN; CD34 ANTIGEN; CD56 ANTIGEN; CD65S ANTIGEN; CD7 ANTIGEN; CYTARABINE; DAUNORUBICIN; FIBRINOGEN RECEPTOR; GLYCOPROTEIN P; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA DR ANTIGEN; IDARUBICIN; INTERLEUKIN 2 RECEPTOR; MICROSOMAL AMINOPEPTIDASE; MITOXANTRONE; PLACEBO; STEM CELL FACTOR RECEPTOR; TIOGUANINE; TRANSFERASE; TUMOR ANTIGEN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; AGING; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW CELL; CANCER SURVIVAL; CELL DIFFERENTIATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; INCIDENCE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MICROMORPHOLOGY; MULTIDRUG RESISTANCE; MYELOBLAST; ONCOLOGY; PERIPHERAL BLOOD STEM CELL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN PROCESSING; STATISTICAL SIGNIFICANCE; TUMOR DIFFERENTIATION;

EID: 0041525832     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402999     Document Type: Article

References (58)

1. Ludwig W-D, Thiel E. Routine immunophenotyping of acute leukemias. Blut 1990; 60: 48-50.
2. Putti MC, Rondelli R, Cocito MG, Aricó M, Sainati L, Conter V et al. Expression of myeloid markers lacks prognostic impact in children treated for acute lymphoblastic leukemia: Italian experience in AIEOP-ALL 88-91 studies. Blood 1998; 92: 795-801.
3. Ludwig W-D, Rieder H, Bartram CR, Heinze B, Schwartz S, Gassmann W et al. Immunophenotypic and genotypic features, clinical characteristics, and treatment outcome of adult Pro-B acute lymphoblastic leukemia: results of the German Multicentre Trials GMALL 03/87 and 04/89. Blood 1998; 92: 1898-1909.
4. Paietta E. Immunobiology of acute leukemia. In: Wiernik P, Dutcher J, Goldman J, Kyle R (eds). Neoplastic Diseases of the Blood, 4th edn. Cambridge, UK: Cambridge University Press, 2003 (in press).
5. Knapp W, Strobl H, Majdic O. Flow cytometric analysis of cell-surface and intracellular antigens in leukemia diagnosis. Cytometry 1994; 18: 187-198.
6. Rowe JM, Andersen JW, Cassileth PA, Oken MM, Bennett JM, Wiernik PH. Post-remission therapy in adults with acute myelogenous leukemia: the Eastern Cooperative Oncology Group (ECOG) experience. Leukemia 1992; 4: 75-77.
7. Rowe JM, Andersen JW, Cassileth PA, Oken MM, Bennett JM, Wiernik PH. Clinical trials in adults with acute myelogenous leukemia: experience of the Eastern Cooperative Oncology Group. In: Büchner T (ed). Acute Leukemias, 4th edn. Berlin: Springer-Verlag, 1994, pp 541-546.
8. Rowe JM, Andersen JW, Mazza JJ, Bennett JM, Paietta E, Hayes FA et al. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: A study of the Eastern Cooperative Oncology Group (E1490). Blood 1995; 86: 457-462.
9. Bennett JM, Young ML, Andersen JW, Cassileth PA, Tallman MS, Paietta E et al. Long-term survival in acute myeloid leukemia. The Eastern Cooperative Oncology Group experience. Cancer 1997; 80: 2205-2209.
10. Cassileth PA, Harrington DP, Appelbaum FR, Lazarus HM, Rowe JM, Paietta E et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 1998; 339: 1649-1656.
11. Bennett JM, Catovsky D, Daniel M-T, Flandrin G, Galton DAG, Gralnick HR et al. Proposed revised criteria for the classification of acute myeloid leukemia. Ann Intern Med 1985; 103: 620-625.
12. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposal for the recognition of minimally differentiated acute myeloid leukemia. Br J Haematol 1991; 78: 325-329.
13. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood 2000; 96: 4075-4083.
14. Kishimoto T, Kikutani H, von dem Borne AWGKr, Goyert SM, Mason DY, Moretta L et al. Leukocyte Typing VI. White Cell Differentiation Antigens. New York: Garland Publishing Inc., 1998.
15. 8Cer. J Biochem 1996; 119: 456-462.
16. Paietta E. Expression of cell surface antigens in APL. In: Tallman MS (ed). Acute Promyelocytic Leukemia, Bailliere's Best Practice & Research: Clinical Haematology. London, UK: Harcourt Publishers Ltd, 2003 (in press).
17. Bene MC, Castoldi G, Knapp W, Ludwig WD, Matutes E, Orfao A et al. Proposals for the immunological classification of acute leukemias. Leukemia 1995; 9: 1783-1786.
18. Paietta E, Andersen J, Wiernik PH. A new approach to analyzing the utility of immunophenotyping for predicting clinical outcome in acute leukemia. Leukemia 1996; 10: 104.
19. Campana D, Behm FG. Immunophenotyping of leukemia. J Immunol Methods 2000; 243: 59-75.
20. Paietta E, Gallagher RE, Wiernik PH. Myeloid/natural killer cell acute leukemia: a previously unrecognized form of acute leukemia potentially misdiagnosed as FAB-M3 acute myeloid leukemia. Blood (Correspondence) 1994; 84: 2824-2825.
21. - myeloid/natural killer cell acute leukemia: a previously unrecognized form of acute leukemia potentially misdiagnosed as French-American-British acute myeloid leukemia-M3. Blood 1994; 84: 244-255.
22. Paietta E, Andersen J, Yunis J, Rowe JM, Cassileth PA, Tallman MS et al. Acute myeloid leukemia expressing the leucocyte integrin CD11b - a new leukemic syndrome with poor prognosis: result of an ECOG database analysis. Br J Haematol 1998; 100: 265-272.
23. Heath CW. Epidemiology and hereditary aspects of acute leukemia. In: Wiernik PH, Canellos GP, Dutcher JP, Kyle RA (eds). Neoplastic Diseases of the Blood, 3rd edn. New York: Churchill Livingstone, 1996, p 177.
24. Rowe JM. Treatment of acute myelogenous leukemia in older adults. Leukemia 2000; 14: 480-487.
25. Head DR. Revised classification of acute myeloid leukemia. Leukemia 1996, 10: 1826-1831.
26. Rowley JD, Alimena G, Garson OM, Hagemeijer A, Mitelman F, Prigogina EL. A collaborative study of the relationship of the morphologic type of acute nonlymphocytic leukemia with patient age and karyotype. Blood 1982; 59: 1013-1022.
27. Goasguen JE, Matsuo T, Cox C, Bennett JM. Evaluation of the dysmyelopoiesis in 336 patients with de novo acute myeloid leukemia: majors importance of dysgranulopoiesis for remission and survival. Leukemia 1992; 6: 520-525.
28. Gahn B, Haase D, Unterhalt M. De novo AML with dysplastic hematopoiesis: cytogenetic and prognostic significance. Leukemia 1996; 10: 937-942.
29. Kahl C, Florschütz A, Müller G, Jentsch-Ullrich K, Arland M, Leuner S et al. Prognostic significance of dysplastic features of hematopoiesis in patients with de novo acute myelogenous leukemia. Ann Hematol 1997; 75: 91-94.
30. Willman CL. Acute leukemias: a paradigm for the integration of new technologies in diagnosis and classification. Mod Pathol 1999; 12: 218-228.
31. Garrido SM, Cooper JJ, Appelbaum FR, Willman CL, Kopecky K, Banker DE. Blasts from elderly acute myeloid leukemia patients are characterized by low levels of culture- and drug-induced apoptosis. Leukemia 2001; 25: 23-32.
32. Venditti A, Del Poeta G, Buccisano F, Tamburini A, Cox-Froncillo MC, Bruno A et al. Biological features of acute myeloid leukemia in the elderly. Blood 1998; 92: 697-698.
33. Stasi R, Laziale A, Del Poeta G, Venditti A, Masi M, Stipa E et al. Prognostic value of cytogenetics and multidrug resistance (MDR1) in elderly patients with acute myeloid leukemia. Blood 1998; 92: 695-705.
34. Ballester O, Moscinski LC, Morris D, Balducci L. Acute myelogenous leukemia in the elderly. J Am Geriatr Soc 1992; 40: 277-284.
35. Harousseau J-L. Acute myeloid leukemia in the elderly. Blood 1998; 12: 145-153.
36. Stasi R, Del Poeta G, Venditti A, Masi M, Stipa E, Dentamaro T et al. Analysis of treatment failure in patients with minimally differentiated acute myeloid leukemia (AML-M0). Blood 1994; 83: 1619-1625.
37. Segeren CM, De Jong-Gerrits GCMM, Van't Veer MB. On behalf of the Dutch Slide Review Committee of Leukemias in Adult AML-M0: clinical entity or waste basket for immature blastic leukemias? A description of 14 patients. Ann Hematol 1995; 70: 297-300.
38. Huang S-Y, Tang J-L, Jou S-T, Tsay W, Hu C-H , Lin D-T et al. Minimally differentiated acute myeloid leukemia in Taiwan: predominantly occurs in children less than 3 years and adults between 51 and 70 years. Leukemia 1999; 13: 1506-1512.
39. Kotylo P, Seo I-S, Smith FO, Heerema NA, Fineberg NS, Miller K et al. Flow cytometric immunophenotypic characterization of pediatric and adult minimally differentiated acute myeloid leukemia (AML-M0). Am J Clin Pathol 2000; 113: 193-200.
40. Villamor N, Zarco M-A, Rozman M, Ribera J-M, Feliu E, Montserrat E. Acute myeloblastic leukemia with minimal myeloid differentiation: phenotypical and ultrastructural characteristics. Leukemia 1998; 12: 1071-1075.
41. Béné M-C, Bernier M, Casasnovas RO, Castoldi G, Doekharan D, Van Der Holt B et al. Acute myeloid leukemia M0: hematological, immunophenotypic and cytogenetic characteristics and their prognostic significance: an analysis in 241 patients. Br J Haematol 2001; 113: 737-745.
42. Cascavilla N, Melillo L, D'Arena G, Greco MM, Carella AM, Sajeva MR et al. Minimally differentiated acute myeloid leukemia (AML-M0): clinico-biological findings of 29 cases. Leukemia Lymphoma 2000; 37: 105-113.
43. Tumours of haematopoietic and lymphoid tissues. Pathology and genetics. In: Jaffe ES, Harris NIL, Stein H, Vardiman JW (eds). World Health Organization Classification of Tumours. Lyon, France: IARC Press, 2001.
44. Stasi R, Amadori S. AML-M0: a review of laboratory features and proposal of new diagnostic criteria. Blood Cells Mol Dis 1999; 25: 120-129.
45. Kaleem Z, White G. Diagnostic criteria for minimally differentiated acute myeloid leukemia (AML-M0). Am J Clin Pathol 2001; 115: 876-884.
46. Cuneo A, Ferrant A, Michaux JL, Booagaerts M, Demuynck H, Van Orshoven A et al. Cytogenetic profile of minimally differentiated (FAB M0) acute myeloid leukemia: correlation with clinicobiologic findings. Blood 1995; 85: 3688-3694.
47. Venditti A, Del Poeta G, Buccisano F, Tamburini A, Cox C, Stasi R et al. Minimally differentiated acute myeloid leukemia (AML-M0): comparison of 25 cases with other French-American-British subtypes. Blood 1997; 89: 621-629.
48. Head DR, Savage RA, Cerezo L, Craven CM, Bickers JN, Hartsock R et al. Reproducibility of the French-American-British classification of acute leukemia: the Southwest Oncology Group experience. Am J Hematol 1985; 18: 47-57.
49. Thalhammer-Scherrer R, Mitterbauer G, Simonitsch I, Jaeger U, Lechner K, Schneider B et al. Relationship to morphologic and molecular classification and proposal for a minimal screening program highly predictive for lineage discrimination. Am J Clin Pathol 2002; 117: 380-389.
50. Chabannon C, Wood P, Torok-Storb B. Expression of CD7 on normal human myeloid progenitors. J Immunol 1992; 149: 2110-2113.
51. Dworzak MN, Fritsch G, Fröschl G, Printz D, Gadner H. Four-color flow cytometric investigation of terminal deoxynucleotidyl transferase-positive lymphoid precursors in pediatric bone marrow: CD79A expression CD19 in early B-cell ontogeny. Blood 1998; 92: 3203-3209.
52. Amadori S, Venditti A, Del Poeta G, Stasi R, Buccisano F, Bruno A et al. Minimally differentiated acute myeloid leukemia (AML-M0): a distinct clinico-biologic entity with poor prognosis. Ann Hematol 1996; 72: 208-215.
53. Legrand O, Perrot JY, Baudard M, Cordier A, Lautier R, Simonin G et al. The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score. Blood 2000; 96: 870-877.
54. Baudard M, Maria JP, Cadiou M, Viguié F, Zittoun R. Acute myelogenous leukaemia in the elderly: retrospective study of 235 consecutive patients. Br J Haematol 1994; 86: 82-91.
55. Stasi R, Venditti A, Del Poeta G, Aronica G, Dentamaro T, Cecconi M et al. Intensive treatment of patients age 60 Years and older with de novo acute myeloid leukemia. Cancer 1996; 77: 2476-2488.
56. Wahlin A, Markevärn B, Golovleva I, Nilsson M. Prognostic significance of risk group stratification in elderly patients with acute myeloid leukaemia. Br J Haematol 2001; 115: 25-33.
57. Venditti A, Buccisano F, Del Poeta G, Maurillo L, Tamburini A, Cox C et al. Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood 2000; 96: 3948-3952.
58. San Miguel JF, Vidriales MB, López-Berges C, Díaz-Mediavilla J, Gutiérrez N, Cañizo C et al. Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood 2001; 98: 1746-1751.